article thumbnail

Arrayjet announces collaboration with Chemspace

Drug Discovery World

Arrayjet and Chemspace have agreed a partnership to augment and streamline Chemspace’s small molecule microarray (SMM) service offering. Chemspace’s compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for assay development, contract screening and contract array manufacturing.

article thumbnail

Tech Focus: How is HTS accelerating early-stage drug discovery?

Drug Discovery World

Now, with HT-SPR, researchers have the ability to screen entire antibody and small molecule libraries, along with characterising epitopes, so there is way more data available at the earliest stages of drug discovery than ever before.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SLAS2024: Day One Highlights

Drug Discovery World

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’.

article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

During a 2021 webinar on optimising assay development for hit identification, a survey asked over 50 drug discovery scientists, “Which goal is the highest priority when developing a drug discovery assay?”. protein-protein or small molecule-target interactions). Opportunities, options, and outsourcing.

article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96
article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.

article thumbnail

Biophysics

Sygnature Discovery

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.